Objective. To investigate the consequences of IGF proteins dysfunction in development of endometrial adenocarcinomas.
Introduction
Under normal circumstances, proteins of the IGF family (IGF 1 and IGF 2, their receptors and binding proteins) regulate cell proliferation, metabolism and maintain differentiated cell function. In addition, in endometrium, the IGF protein system is thought to function as a mediator of steroid hormone actions through autocrine/paracrine mechanisms. Namely, endometrial stroma cells produce IGF 1 and IGF 2 as well as high affinity IGFbinding proteins (IGF BPs), the most abundant being IGF BP-1, whereas epithelial cells and, to a lesser extend, stromal cells contain cell membrane receptors for IGF's. On the other hand, estrogen stimulates IGF 1/IGF 1R gene expression, associated with endometrial carcinoma development [1] .
The IGF 1 and IGF 2 signaling pathway involve two specific receptors. IGF 1R (which is virtually ubiquitous) mediates IGF 1 and IGF 2 action on prenatal growth and IGF 1 action on postnatal growth. On the other hand, as far as IGF ligands are concerned, IGF 2R/M6-P is involved in the clearance of IGF 2 from the circulation. Furthermore, at least six IGF-binding proteins (IGF BP 1-6) also regulate the function of both, IGF 1 and IGF 2. It is obvious from the above mentioned, that the inappropriate expression of any IGF peptide could be involved in abnormal cell function. It is known that not only IGF 2, but also IGF 1R, are commonly overexpressed in many tumors. As their appropriate level and/or interaction regulate cell growth, it is obvious that overexpression of either of them (or both) may be involved in enhanced tumor growth [2] . The proposed mechanism of autocrine IGF 2 action on malignant proliferation came from its elevated secretion by tumors and tumor derived cell lines [3, 4] .
On the other hand, the physiological significance of IGF 1R activation by either IGF 1 or IGF 2 was brought into focus by gene targeting experiments in mice [5] . Mice with homozygous targeted mutations of the IGF 1 receptor were severely growth retarded and died immediately after birth, indicating these receptors are important for cell proliferation and survival. Later it was also shown that signaling through these tyrosine kinase growth factor receptors is one of the key regulators of cell motility and adhesion. However, functional IGF 1R is also required for cell transformation, which appears to involve autocrine stimulation through overexpressed IGF 1R, at least in tumors of epithelial origin [6] . Moreover, it has been shown that a blockade of the IGF 1R function reverses the transformed phenotype of tumors derived from both experimental animals and humans [7, 8] .
Contrary to the already mentioned IGF 2/IGF 1R oncogenic action, IGF 2R/M6-P protects the cells from neoplastic impulses, at least those caused by IGF 2. Namely, the binding of IGF 2 to IGF 2R/M6-P results in the degradation of ligand, making it unable to activate IGF 1R. However, IGF 2R/M6-P has been shown to be mutated in a number of human tumors, identifying it as a tumor suppressor.
In developed countries, adenocarcinoma of the endometrium is the most common gynecological cancer. Histopathologically, it is characterized by the proliferation of abnormal glands in an abnormal relationship to one another. Evidence has been accumulated that links IGF family peptides with the development of this tumor type. However, their exact role in endometrial adenocarcinoma development is still unclear.
The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R and IGF 2R/M6-P) in endometrial adenocarcinoma. We measured expression of IGF 2 and its receptors mRNA in order to analyze the possible correlation among these genes activity and cell proliferation, as well as the tumor stage. As disruption of the IGF 2/IGF 1R pathway can be accomplished through the binding of growth factors, blockage of receptors or inhibition of secondary targets, we also examined the effect of IGF 1 receptor blockage by αIR3 monoclonal antibodies or antisense oligodeoxynucleotides on cell proliferation. An additional purpose of our investigation was to determine if IGF 2R/M6-P is a target for mutation. Our data suggest that increased expression of IGF 1, IGF 2 and IGF 1R may be an important 
Materials and Methods

Tumor tissues
Ten endometrial hyperplasias and 91 human primary endometrial adenocarcinomas (Table 1) .
Seven normal post-menopausal endometrial tissue specimens were used as a control for mRNA analysis.
For the proliferation assay, [ 
Immunohistochemistry
This was performed on formalin-fixed, paraffin-embedded tissue using the avidinbiotin-peroxidase method. Sections, cut at 4 µm, were subjected to a heat-induced epitope retrieval technique in 10 mM citrate buffer (pH 6.0) in an 850 W microwave oven for 10 minutes. Anti-IGF1 (goat; 50 µg/ml; R&D Systems), anti-IGF 2 (mouse, Upstate Biotechnologies, Lake Placid, N.Y) and anti-Ki-67 (mouse, 10 µg/ml; DAKO Cytometrics, Denmark) monoclonal antibodies were diluted 1:50, and incubated for 15 to 18 hours. Anti IGF 1R (Santa Cruz Biotechnologies, Santa Cruz, CA) was diluted 1:100 and incubated for 15-18 hours. Detection was achieved using the DAKO LSAB 2 kit (Carpinteria, CA). Anti IGF 2R/M6P rabbit polyclonal antibody was a generous gift from Zeneco, USA 
RNA extraction and RNase protection assay
Total RNA extraction was performed as described previously [9] . Tissue mRNA for IGF 2 and IGF 1R was analyzed by an RNase protection assay. A sample of total RNA (20 µg) was hybridized in a buffer containing 80% formamide, molar excess of [ 
Loss of Heterozygosity Analysis and Mutation Detection in IGF 2R/M6P
We utilized two polymorphisms, dinucleotide (GT) repeat sequence and a tetranucleotide insertion/deletion (ACAA) site, present in the 3'-untranslated region of the human IGF 2R/M6P gene, to determine the frequency of LOH [11] . The reaction conditions for PCR, primer sequences and a detailed method description have been published previously [12] .
In tumors with LOH at one IGF 2R/M6P locus, the remaining allele was screened for mutations in the ligand binding regions by direct sequencing of PCR products [13] . The regions screened for mutations were exons 8-11, exons 27-29, exon 31, exons 33 and 34 and exons 37-39. The exon specific forward and reverse PCR primers that were used have been published [14] .
Cultivation of tumor cells
Tumor tissue, without necroses, was cut into small pieces and pressed through a nylon sieve. Cells (approximately 4 x 10 5 ) were put into T75 flasks covered with an extracellular matrix with an RPMI medium supplemented with 10% fetal bovine serum, 5% human serum, 1% glutamine, and 20 mM HEPES. Tumor cell cultures were maintained as monolayers [15] .
Cell proliferation and apoptosis after blocking of IGF 2/IGF 1R by monoclonal antibodies or antisense oligodeoxynucleotides.
Tumor cell proliferation was evaluated by [
Analysis of Apoptosis
A FACScan apoptosis analysis was performed as described previously [16] . Two 
Telomerase assay
The telomerase assay was performed with a commercial telomerase PCR ELISA kit (Roche Molecular Biochemicals, Indianapolis, IN) in accordance with Bosserhoff et al [17] and the manufacturer's protocol. Absorbance at 450 nm was measured using an ELISA plate reader (Labsystems, Multiscan MS) [18] . Cells were lysed and protein concentrations were determined by Bradford assay. Two µg of protein were used for each telomerase PCR reaction. Telomerase assay was also performed using positive and negative controls as specified in the kit.
Statistical analysis
Data are shown as mean ± standard deviation. A Student's t-test was performed to compare the results between different groups of samples. The normality of the data was tested by Kolmogorov test. The assumption of equal group variances was tested with Levene's test.
In the case of violated assumptions for the analysis, the maximum likelihood analysis suggested the optimal transformation data.
Results
Expression of IGF 2 and IGF 1R mRNA and Apoptosis
The expression of the IGF 2 and IGF 1R gene mRNA was much higher in malignant than in normal or hyperplastic endometrial tissue (p<0.001). Moreover, it was significantly higher in stages III and IV versus cancers of stages I and II (p<0.001, Fig. 1 ).
The immunohistochemical analysis of IGF 2, IGF 1R, as well as IGF 2R/M6-P protein Table 4 ).
The effect of the IGF 1 receptor blocking antibody on cell proliferation is shown in Table 5 . In IGF 2 positive cells, cell proliferation was strongly diminished. On the contrary, there was no statistically different effect of αIR3 treatment on IGF 2 negative cell culture.
To ascertain the role of IGF 2 and IGF 1R as a potential mediator in growth promotion, 2 endometrial adenocarcinomas positive for IGF 2 mRNA and one negative, grown in vitro, were treated with sense and antisense oligodeoxynucleotides to IGF 1R or IGF 2 mRNA (Table 5) . Antisense oligodeoxynucleotides to IGF 2 in concentration of 20 µM significantly reduced the growth of both cell lines for 95% and 85%, respectively. At a concentration of 10 µM, antisense oligodeoxynucleotides to IGF 1R also inhibited the growth of both tested cell lines by 46% and as much as 86%. Contrary to this, sense oligodeoxynucleotides to IGF 2 or IGF 1R had no effect on tumor cell proliferation. There was no effect of either antisense or sense deoxyoligonucleotides on either IGF 2 or IGF 1R in IGF 2 negative cells.
The relationship among IGF 1/IGF 2/IGF 1R protein and telomerase activity and proliferation index
The positive correlation between the increased expression of protein for both IGF 1 and IGF 1R and increased telomerase activity (p<0.0267 for IGF1 and p<0.3707 for IGF 1R) and the cell proliferation index (p<0.3707 for IGF 1 and p=05. for IGF 1R) was found in all eleven IGF 2 positive endometrial adenocarcinomas of stages III and IV. Similar results were also observed in a group of 21 IGF 2 negative tumors of stages III and IV (IGF 1/telomerase p<0.0062; IGF 1R/telomerase p<0.0515; IGF 1/Ki-67 p<0.0001; IGF 1R/Ki-67 p<0.0013) ( Table 6 ).
Discussion
IGF 1 and 2 secreted by tumor cells play a major role in tumor progression mostly through the binding and activation of IGF 1R. Such an interplay has been shown in a variety of human tumors. Here we provide the evidence on the role of IGF system in endometrial malignancy and provide novel insights into the complex mechanisms that contribute to its oncogenic potential.
In our study, the majority of endometrial adenocarcinomas overexpressed IGF 1/IGF 2 and/or IGF 1R. At the same time, these tumors, especially those of advanced stages, failed to express IGF 2R. Together with the fact that almost all such samples had a decreased apoptosis rate, the increased proliferation index, as well as increased telomerase activity, indicate the important role of proteins of the IGF family in the pathogenesis of endometrial adenocarcinoma. Similar finding were also shown for colon [3] , lung [8] , gastric [10] and gynecological cancers [19] , as well as hemangiopericytomas [20] . Furthermore, all these data [26] showed that in HEC-1A endometrial adenocarcinoma cells responsive to IGF 1, the IGF BP3 is the main binding protein expressed, and both soluble and cell-associated forms act as inhibitors of IGF 1-induced cellular proliferation. In addition to IGF BPs, insulin, as well as nutritional energy balance and physiological activity levels, appears to be an important determinant of IGF 1 bioactivity [27] .
When expressed normally, IGF 2 is an indispensable mitogenic peptide for a number of cell types. However, there are now a number of disease situations in which the level of IGF 2 is elevated, leading to increased cell proliferation and inhibition of apoptosis, as seen in many human and animal tumors. In endometrial adenocarcinoma, the IGF 2 protein/mRNA level is also increased [21, 25] Although the exact meaning of these findings and the role of IGF 2 in the etiology of endometrial cancer is still unclear, the accumulated evidence points to its autocrine stimulation through IGF 1R, which is an absolute requirement for at least the maintenance of the transformed phenotype. In support to this possibility, there are also the results presented in this paper. The concomitant elevated expression of IGF 2 (sometimes associated with elevated IGF 1) and IGF 1R resulted in an increased proliferation rate and telomerase activity, and a decreased apoptosis rate of cancer cells, all characteristics of neoplastic growth. Additionally, when the IGF 2 and/or receptor function was blocked by using monoclonal antibodies or antisense oligonucleotides, the cell growth in vitro was efficiently abrogated, showing for the first time that these two kinds of targeted therapies can be successfully applied to the treatment of endometrial adenocarcinoma. As far as we know there are only limited data on targeted therapy of endometrial adenocarcinoma. So it was shown that the growth of endometrial adenocarcinoma cells can also be inhibited by the use of the LH-RH antagonist SB-75 (Ac-D-Nal (2) [28] . This interferes with the autocrine activity of IGF 2 and also directly inhibits the growthstimulatory effects of IGFs, probably through effects on a post-receptor mechanism. Of a special clinical interest might also be the finding that overexpressed IGF 1R signaling might provoke resistance to trastuzumab (Herceptin) an anti HER2/neu receptor monoclonal antibody [29] , main drug for treatment breast cancer overexpressing HER2/neu receptors.
However, amplification of HER2/neu has also been reported for endometrial cancer, and trastuzumab is currently under Phase II clinical trial for stage III and IV, and recurrent endometrial adenocarcinoma.
All together, ours, as well as other experiments have unequivocally shown that a decrease in the level of IGF 2 and number of IGF IR causes a reversal of the transformed phenotype [7, 8, 10, 12, 30] .
The mechanism by which the IGF 2 gene is overexpressed in endometrial adenocarcinomas presented in this paper was not explored. However, it is known that IGF 2 overexpression can be accomplished by multiple mechanisms such as loss of imprinting (LOI), loss of heterozygosity (LOH) with paternal duplication, and alteration in IGF-binding proteins [31] . Which of the mechanisms underlay IGF 2 overexpression in endometrial adenocarcinoma is still in question, although biallelic expression was shown to occur in some (3 out of 12 tested) endometrial tumor samples [32] . However, as LOI did not correlate with IGF 2 mRNA overexpression, the authors of these results suggested «that biallelic expression of IGF 2 may be subject to down regulation, despite loss of imprinting».
Consistent with the IGF's autocrine regulation of endometrial adenocarcinoma growth are also the findings of mutations in IGF 2R gene reported previously to be present in 15% of examines samples [33] . Expressed at the cell surface, IGF 2R is constitutively endocytosed, where its main role is binding and internalization and subsequent degradation of nonglycosylated IGF 2. As shown in this paper, the mutated IGF 2R gene caused decrease in the level of corresponding protein, which was a more common event in advanced stages of endometrial adenocarcinoma. As these changes were associated with the concomitant overexpression of IGF 2/IGF 1R, it is very likely that the IGF 2R gene acts as a tumor suppressor in endometrial adenocarcinoma, similar to what has been shown for some other human tumors. Namely, biallelic mutations, usually point mutation or small deletion in one allele and loss of heterozygosity in the other, have been reported in a variety of human malignancies, including hepatocarcinoma and adrenocortical tumors [34, 35] , aggressive early breast cancer [36] , and lung cancers [12, 13] . Furthermore, the IGF2/M6P locus at 6q has been reported to be a hot spot for mutation in tumors, including malignant melanoma [37] , ovarian cancer [38] non-Hodgkin lymphoma [39] , and renal cell carcinoma [40] . Down regulation of the IGF 2R/M6P promotes the growth of transformed cells by sustaining IGF 2, which binds to and activates IGF 1R and the insulin receptor to increase intracellular growth signals [41] . However, it has also been shown that IGF 2R/M6P is a receptor for granzyme B during immune system mediated apoptosis [42] . Therefore, tumor cell lines deficient in functional IGF 2R/M6P would also have an inherent resistance to the immune system, which could contribute to the easier tumor development. In support of this belief, there is also the observation that IGF 2R/M6P is secreted by breast cancer lines and primary metastatic breast cancer cells [43] . If it is supposed that granzyme could also bind to this soluble form of IGF In conclusion, our results support the hypothesis that the production of IGF 1, IGF 2, IGF 1R, and IGF 2R, different from that in normal tissue, influence endometrial adenocarcinoma growth by autocrine mechanism. Tumor cells overexpress IGF 1R which efficiently binds, also overexpressed, IGF 2, since IGF 2 "clearance"-IGF 2R are at the same time underexpressed and/or nonfunctional. These lead to increased telomerase activity, and the inversion of the balanced proliferation/apoptosis rate usual for normal cells. The already described loop can be abrogated by targeted therapy. HYPERPLASIA  1  2  3  4  5  6  7  8  9  10   3  3  3  3  3  3  3  3  2  3  3  3  2  2  2  1  1  1  1  1  1  1  0  0  0   0  0  0  1  1  1  1  2  2  2   3  3  3  2  3  3  3  3  3  3  2  2  2  1  1  2  1  2  2  2  1  2  2  2  1   0  0  1  1  2  2  2  1  2  3   0  0  0  0  1  1  1  1  1  2  2  3  2  3  2  3  3  1  3  2  2  3  3  2  3   2  2  2  2  2  3  3  3  3  1   13  12  19  19  26  18  10  15  30  49  17  31  25  51  29  66  58  44  37  41  40  32  63  60  70   44  38  70  47  39  69  59  50  55  46 * stages III and IV 
